Zogenix hit on Purdue abuse-deterrent hydrocodone priority review
This article was originally published in Scrip
Executive Summary
Purdue Pharma could have a decision by October from the FDA on the company's once-daily, single-entity hydrocodone bitartrate tablet, currently dubbed HYD, under a priority review – news that hit potential competitor Zogenix hard.